Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Roche Seeks FDA Approval for Skin Cancer Drug, Frings Says

Sept. 12 (Bloomberg) -- Roche Holding AG submitted an experimental drug to treat a form of skin cancer to the U.S. Food and Drug Administration for approval.

The filing for vismodegib to treat advanced basal cell carcinoma was based on a study to be presented at the European Multidisciplinary Cancer Congress next week, Stefan Frings, Roche’s oncology head, said in an interview today at the company’s headquarters in Basel, Switzerland.

The drug shrunk tumors and healed lesions in patients whose cancer had progressed too far to be removed with surgery, Roche said in a statement today. There are currently no treatments for those patients, Roche said. The company is also studying vismodegib in people whose cancer is still operable.

The Swiss drugmaker is developing vismodegib under an agreement with Lexington, Massachusetts-based Curis Inc. The U.S. company is eligible to receive $8 million from Roche upon FDA acceptance of the submission, Curis said in a separate statement. Curis also will receive an additional payment if the drug is approved, as well as royalties on any sales.

To contact the reporter on this story: Naomi Kresge in Basel, Switzerland, via nkresge@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.